Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors

NCT04735978 is registered in ClinicalTrials.gov with Replimune, Inc. as lead sponsor.

NCT NCT04735978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04735978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1 Study of RP3 as a Single Agent and in Combination With PD-1 Blockade in Patients With Solid Tumors
Lead sponsor
Replimune, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 29, 2020
Completion date
November 30, 2026
Enrollment
123 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor